亚太药业: 2025年半年度业绩预告

Summary of Key Points Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. expects a significant increase in net profit compared to the previous year, but a decline in net profit after deducting non-recurring losses due to market competition and financial costs related to convertible bonds [1][2]. Financial Performance - Estimated net profit for the current period is between 100 million to 110 million yuan, compared to 5.4752 million yuan in the same period last year, indicating a growth of 1726.42% to 1909.06% [1]. - Estimated net profit attributable to shareholders after deducting non-recurring losses is projected to be between -44 million to -54 million yuan, a decline of 462.18% to 589.95% from a loss of 7.8267 million yuan in the previous year [1]. - Estimated operating revenue is between 150 million to 155 million yuan, down from 221.9333 million yuan in the same period last year [1]. - Basic earnings per share are expected to be between 0.1357 yuan to 0.1492 yuan, compared to 0.01 yuan per share in the previous year [1]. Reasons for Performance Changes - The decline in net profit after deducting non-recurring losses is primarily due to: 1. Decreased sales revenue influenced by centralized procurement and intensified market competition [1]. 2. Increased financial expenses due to the redemption of unconverted convertible bonds, which were redeemed at 115% of their face value, leading to additional costs [1].